A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination

Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazrafshan, Hanieh, Mohamadi Jahromi, Leila Sadat, Parvin, Reyhaneh, Ashraf, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366477/
https://www.ncbi.nlm.nih.gov/pubmed/35989967
http://dx.doi.org/10.5606/tftrd.2022.9984
_version_ 1784765574508707840
author Bazrafshan, Hanieh
Mohamadi Jahromi, Leila Sadat
Parvin, Reyhaneh
Ashraf, Alireza
author_facet Bazrafshan, Hanieh
Mohamadi Jahromi, Leila Sadat
Parvin, Reyhaneh
Ashraf, Alireza
author_sort Bazrafshan, Hanieh
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which started three to four days after receiving the second dose of Oxford/AstraZeneca vaccine against the COVID-19 infection. The acute inflammatory demyelinating polyradiculoneuropathy subtype of the Guillain-Barre syndrome, which is the most common subtype, was diagnosed. Regardless of the beneficial effects of the vaccines, this case report aimed to evaluate their severe complications, such as Guillain-Barre syndrome, to reduce their occurrence in the future.
format Online
Article
Text
id pubmed-9366477
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bayçınar Medical Publishing
record_format MEDLINE/PubMed
spelling pubmed-93664772022-08-18 A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination Bazrafshan, Hanieh Mohamadi Jahromi, Leila Sadat Parvin, Reyhaneh Ashraf, Alireza Turk J Phys Med Rehabil Case Report Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which started three to four days after receiving the second dose of Oxford/AstraZeneca vaccine against the COVID-19 infection. The acute inflammatory demyelinating polyradiculoneuropathy subtype of the Guillain-Barre syndrome, which is the most common subtype, was diagnosed. Regardless of the beneficial effects of the vaccines, this case report aimed to evaluate their severe complications, such as Guillain-Barre syndrome, to reduce their occurrence in the future. Bayçınar Medical Publishing 2022-06-01 /pmc/articles/PMC9366477/ /pubmed/35989967 http://dx.doi.org/10.5606/tftrd.2022.9984 Text en Copyright © 2022, Turkish Society of Physical Medicine and Rehabilitation https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Report
Bazrafshan, Hanieh
Mohamadi Jahromi, Leila Sadat
Parvin, Reyhaneh
Ashraf, Alireza
A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
title A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
title_full A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
title_fullStr A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
title_full_unstemmed A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
title_short A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination
title_sort case of guillain-barre syndrome after the second dose of astrazeneca covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366477/
https://www.ncbi.nlm.nih.gov/pubmed/35989967
http://dx.doi.org/10.5606/tftrd.2022.9984
work_keys_str_mv AT bazrafshanhanieh acaseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT mohamadijahromileilasadat acaseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT parvinreyhaneh acaseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT ashrafalireza acaseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT bazrafshanhanieh caseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT mohamadijahromileilasadat caseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT parvinreyhaneh caseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination
AT ashrafalireza caseofguillainbarresyndromeaftertheseconddoseofastrazenecacovid19vaccination

Ejemplares similares